Immunodermatology News

The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection.

Low doses of glucocorticoids added to immunosuppression yield no significant benefit for skin fibrosis in early diffuse cutaneous systemic sclerosis, according to data published in Arthritis Care & Research.

An in-depth interview about the effects of the CMS’s 2025 physician fee schedule on patient access topped Healio Dermatology’s most-read articles of November, with FDA news also garnering attention.

The CMS finalized cuts to the 2025 physician fee schedule for the fifth year in a row, prompting an urgent call-to-action from the American Academy of Dermatology. HHS, through the CMS, announced the finalization of the 2025 Medicare Physician Fee Schedule.

Celebrity news and nutrition stories led Healio Dermatology’s most-read articles in August.

Researchers identified a gene signature that can predict which group of patients with melanoma will experience severe immune-related adverse events when treated with immune checkpoint inhibitor therapy, according to a study.

Dermatologic surgery wounds that were exposed to water in the hours following surgery did not experience an increase in infection, hematoma or bruising, according to a study.

Healio has compiled July’s most-read news in dermatology.

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended the launch of proposed biosimilar rituximab candidate Ituxredi, Dr. Reddy’s Laboratories announced in a press release.